Prevalence of adiposity-based chronic disease in middle-aged adults from Czech Republic: The Kardiovize study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F21%3A00075202" target="_blank" >RIV/00159816:_____/21:00075202 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/21:43921454 RIV/00064203:_____/21:10427261 RIV/00216208:11130/21:10427261 RIV/00064173:_____/21:N0000206 RIV/00216224:14110/21:00121638

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1002/osp4.496" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/osp4.496</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/osp4.496" target="_blank" >10.1002/osp4.496</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prevalence of adiposity-based chronic disease in middle-aged adults from Czech Republic: The Kardiovize study

Popis výsledku v původním jazyce

Aims/Hypothesis The need for understanding obesity as a chronic disease, its stigmatization, and the lack of actionability related to it demands a new approach. The adiposity-based chronic disease (ABCD) model is based on adiposity amount, distribution, and function, with a three stage complication-centric rather than a body mass index (BMI)-centric approach. The prevalence rates and associated risk factors are presented. Methods In total, 2159 participants were randomly selected from Czechia. ABCD was established as BMI &gt;= 25 kg/m(2) or high body fat percent, or abdominal obesity and then categorized by their adiposity-based complications: Stage 0: none; Stage 1: mild/moderate; Stage 2: severe. Results ABCD prevalence was 62.8%. Stage 0 was 2.3%; Stage 1 was 31.4%; Stage 2 was 29.1%. Comparing with other classifiers, participants in Stage 2 were more likely to have diabetes, hypertension, and metabolic syndrome than those with overweight, obesity, abdominal obesity, and increased fat mass. ABCD showed the highest sensitivity and specificity to detect participants with peripheral artery disease, increased intima media, and vascular disease. Conclusion/Interpretation The ABCD model provides a more sensitive approach that facilitates the early detection and stratification of participants at risk compared to traditional classifiers.

Název v anglickém jazyce

Prevalence of adiposity-based chronic disease in middle-aged adults from Czech Republic: The Kardiovize study

Popis výsledku anglicky

Aims/Hypothesis The need for understanding obesity as a chronic disease, its stigmatization, and the lack of actionability related to it demands a new approach. The adiposity-based chronic disease (ABCD) model is based on adiposity amount, distribution, and function, with a three stage complication-centric rather than a body mass index (BMI)-centric approach. The prevalence rates and associated risk factors are presented. Methods In total, 2159 participants were randomly selected from Czechia. ABCD was established as BMI &gt;= 25 kg/m(2) or high body fat percent, or abdominal obesity and then categorized by their adiposity-based complications: Stage 0: none; Stage 1: mild/moderate; Stage 2: severe. Results ABCD prevalence was 62.8%. Stage 0 was 2.3%; Stage 1 was 31.4%; Stage 2 was 29.1%. Comparing with other classifiers, participants in Stage 2 were more likely to have diabetes, hypertension, and metabolic syndrome than those with overweight, obesity, abdominal obesity, and increased fat mass. ABCD showed the highest sensitivity and specificity to detect participants with peripheral artery disease, increased intima media, and vascular disease. Conclusion/Interpretation The ABCD model provides a more sensitive approach that facilitates the early detection and stratification of participants at risk compared to traditional classifiers.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

OBESITY SCIENCE &amp; PRACTICE

ISSN

2055-2238

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

535-544

Kód UT WoS článku

000647238400001

EID výsledku v databázi Scopus

—